Telomerase targeted therapy in cancer and cancer stem cells.

Telomerase plays a key role in cell fate: loss of telomerase in normal differentiated cells heralds senescence and limits cell division, whereas reactivation of telomerase sustains proliferation and potentiates mutagenesis and transformation. Given this pivotal role, telomerase has been the subject of intense investigation in the field of developmental cancer therapeutics. To date, a broad spectrum of therapeutic strategies has been developed, ranging from direct targeting or reprogramming of the enzyme, to immune or virus-mediated targeting of cells expressing telomerase, to strategies focusing on the telomeres themselves. The recent discovery and growing interest in cancer stem cells has thrust telomerase therapy into new relief as an approach that may be uniquely suited to neutralizing this treatment-resistant subpopulation of cancer cells. Here we will review the mechanistic rationale and preclinical and clinical state of development of the various telomerase-based therapeutic approaches, with emphasis on the role of telomerase in cancer stem cell biology and its implications for therapeutic efforts.

[1]  Z. Tao,et al.  Alternative lengthening of telomeres in hTERT‐inhibited laryngeal cancer cells , 2010, Cancer science.

[2]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[3]  S. Spiegl-Kreinecker,et al.  Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes , 2003, Melanoma research.

[4]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[5]  William C Hahn,et al.  Establishment : adaptation to culture and immortalization , 2002 .

[6]  K. Collins The biogenesis and regulation of telomerase holoenzymes , 2006, Nature Reviews Molecular Cell Biology.

[7]  O. Nanni,et al.  Relevance of urine telomerase in the diagnosis of bladder cancer. , 2005, JAMA.

[8]  R. Weinberg,et al.  Cancer stem cells: mirage or reality? , 2009, Nature Medicine.

[9]  M. Manns,et al.  A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma , 2010, BMC Cancer.

[10]  J. Yates,et al.  Quantitative Mass Spectrometry Identifies Drug Targets in Cancer Stem Cell‐Containing Side Population , 2008, Stem cells.

[11]  Stephen Neidle,et al.  The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. , 2005, Cancer research.

[12]  E. Blackburn,et al.  A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. DeMichele,et al.  Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. , 2007, Cancer research.

[14]  C. Harley,et al.  Extension of life-span by introduction of telomerase into normal human cells. , 1998, Science.

[15]  J. Hipp,et al.  Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Robert A. Weinberg,et al.  Creation of human tumour cells with defined genetic elements , 1999, Nature.

[17]  M. Oshimura,et al.  Telomerase activity significantly correlates with cell differentiation, proliferation and lymph node metastasis in colorectal carcinomas , 1998, Journal of Cancer Research and Clinical Oncology.

[18]  C. Harley,et al.  A novel telomerase template antagonist (GRN163) as a potential anticancer agent. , 2003, Cancer research.

[19]  W. Hahn,et al.  Inhibition of telomerase limits the growth of human cancer cells , 1999, Nature Medicine.

[20]  Aleksandar Dakic,et al.  Tumor Growth Need Not Be Driven by Rare Cancer Stem Cells , 2007, Science.

[21]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[22]  J. Shay,et al.  Telomerase activity in gastric cancer. , 1995, Cancer research.

[23]  C. Harley,et al.  The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. , 2010, Cancer research.

[24]  D. Bearss,et al.  Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Donna Niedzwiecki,et al.  Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer 1 , 2005, The Journal of Immunology.

[26]  Lingjun Meng,et al.  Tumor-initiating function of nucleostemin-enriched mammary tumor cells. , 2010, Cancer research.

[27]  Masaharu Akiyama,et al.  Antitumor activity of G-quadruplex-interactive agent TMPyP4 in K562 leukemic cells. , 2007, Cancer letters.

[28]  J. Kigawa,et al.  Alteration of Telomerase Activity Associated With Development and Extension of Epithelial Ovarian Cancer , 1998, Obstetrics and gynecology.

[29]  T. Lange Lasker Laurels for Telomerase , 2006, Cell.

[30]  M. Robinson,et al.  Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. , 1999, Genes & development.

[31]  H. Kato,et al.  Telomerase activity in lung cancer cells obtained from bronchial washings. , 1998, Journal of the National Cancer Institute.

[32]  Carol W. Greider,et al.  Identification of a specific telomere terminal transferase activity in tetrahymena extracts , 1985, Cell.

[33]  Hailong Wu,et al.  Expression of ABCG2 (BCRP) Is Regulated by Nrf2 in Cancer Cells That Confers Side Population and Chemoresistance Phenotype , 2010, Molecular Cancer Therapeutics.

[34]  J. Shay,et al.  The effects of telomerase inhibition on prostate tumor‐initiating cells , 2010, International journal of cancer.

[35]  Chun-Peng Liao,et al.  Reprogramming Murine Telomerase Rapidly Inhibits the Growth of Mouse Cancer Cells In vitro and In vivo , 2010, Molecular Cancer Therapeutics.

[36]  H. Eguchi,et al.  In Situ Telomerase Activity in Pancreatic Juice May Discriminate Pancreatic Cancer From Other Pancreatic Diseases , 2008, Pancreas.

[37]  H. Stein,et al.  Telomerase as a prognostic marker in breast cancer: high‐throughput tissue microarray analysis of hTERT and hTR , 2002, The Journal of pathology.

[38]  D. Amadori,et al.  Potential of telomerase expression and activity in cervical specimens as a diagnostic tool , 2005, Journal of Clinical Pathology.

[39]  K. Chayama,et al.  Establishment of functional telomerase immortalized human hepatocytes and a hepatic stellate cell line for telomere‐targeting anticancer drug development , 2010, Cancer science.

[40]  W. Hahn,et al.  Roots and stems: stem cells in cancer , 2006, Nature Medicine.

[41]  J. Marks,et al.  Telomerase activity and prognosis in primary breast cancers. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Krešo,et al.  Cancer stem cells in solid tumors: an overview. , 2009, Seminars in radiation oncology.

[43]  Stephen Lam,et al.  Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. , 2007, Cancer research.

[44]  N. Maizels,et al.  Gene function correlates with potential for G4 DNA formation in the human genome , 2006, Nucleic acids research.

[45]  R. Stewart,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[46]  S. Aamdal,et al.  Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer , 2006, Cancer Immunology, Immunotherapy.

[47]  B. Hero,et al.  Telomerase activity distinguishes between neuroblastomas with poor prognosis , 1999 .

[48]  I. Svane,et al.  Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. , 2010, Cytotherapy.

[49]  J. Londoño-Vallejo,et al.  Growth defects in mouse telomerase RNA-deficient cells expressing a template-mutated mouse telomerase RNA. , 2009, Cancer letters.

[50]  H. Niiyama,et al.  Telomerase activity in pancreatic juice differentiates ductal carcinoma from adenoma and pancreatitis. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  K. Collins,et al.  Specificity and Stoichiometry of Subunit Interactions in the Human Telomerase Holoenzyme Assembled In Vivo , 2010, Molecular and Cellular Biology.

[52]  Ruth I. Tennen,et al.  Conditional telomerase induction causes proliferation of hair follicle stem cells , 2005, Nature.

[53]  B. Gilchrest,et al.  Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells , 2007, Breast Cancer Research.

[54]  S. Litvinov,et al.  The biology of the 17–1A antigen (Ep-CAM) , 1999, Journal of Molecular Medicine.

[55]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[56]  J. Burdick,et al.  In situ hybridization for telomerase RNA in routine cytologic brushings for the diagnosis of pancreaticobiliary malignancies. , 1998, Gastrointestinal endoscopy.

[57]  J. Shay,et al.  Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. , 2001, Nucleic acids research.

[58]  J. Shay,et al.  High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  E. Blackburn,et al.  Rapid Inhibition of Cancer Cell Growth Induced by Lentiviral Delivery and Expression of Mutant-Template Telomerase RNA and Anti-telomerase Short-Interfering RNA , 2004, Cancer Research.

[60]  K. Shin‐ya,et al.  (S)-stereoisomer of telomestatin as a potent G-quadruplex binder and telomerase inhibitor. , 2011, Organic & biomolecular chemistry.

[61]  M. Tan,et al.  Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. , 2011, Blood.

[62]  A. Cesario,et al.  Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. , 2009, Current medicinal chemistry.

[63]  Alexander Roesch,et al.  A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.

[64]  G. Z. Cheng,et al.  Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. , 2007, Cancer research.

[65]  K. Collins,et al.  A telomerase component is defective in the human disease dyskeratosis congenita , 1999, Nature.

[66]  E. Maher,et al.  The Telomerase Antagonist, Imetelstat, Efficiently Targets Glioblastoma Tumor-Initiating Cells Leading to Decreased Proliferation and Tumor Growth , 2010, Clinical Cancer Research.

[67]  J. Shay,et al.  Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again. , 2002, Differentiation; research in biological diversity.

[68]  A. Marchetti,et al.  Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  A. Meeker,et al.  Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. , 2006, Urologic oncology.

[70]  A. Goldkorn,et al.  Cancer Cells Cyclically Lose and Regain Drug-Resistant Highly Tumorigenic Features Characteristic of a Cancer Stem-like Phenotype , 2011, Molecular Cancer Therapeutics.

[71]  T. Lange,et al.  Shelterin: the protein complex that shapes and safeguards human telomeres , 2005 .

[72]  Alessandro Lugli,et al.  Frequent EpCam protein expression in human carcinomas. , 2004, Human pathology.

[73]  E. Gilson,et al.  G-Quadruplex Ligand RHPS4 Potentiates the Antitumor Activity of Camptothecins in Preclinical Models of Solid Tumors , 2008, Clinical Cancer Research.

[74]  J. Shay,et al.  Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts , 1989, Molecular and cellular biology.

[75]  J. Shay,et al.  Telomerase activity for the preoperative diagnosis of pancreatic cancer. , 1997, Journal of the National Cancer Institute.

[76]  Robin C. Allshire,et al.  Telomere reduction in human colorectal carcinoma and with ageing , 1990, Nature.

[77]  J. Shay,et al.  Telomerase activity as a marker of breast carcinoma in fine‐needle aspirated samples , 2000, Cancer.

[78]  M. Cerone,et al.  Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability , 2001, Oncogene.

[79]  Bo Lu,et al.  A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. , 2010, Cancer research.

[80]  I. Dokal,et al.  Dyskeratosis congenita: a genetic disorder of many faces , 2007, Clinical genetics.

[81]  Haruo Tanaka,et al.  Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. , 2010, Anticancer research.

[82]  S. Neidle,et al.  A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. , 2002, Molecular pharmacology.

[83]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[84]  C B Harley,et al.  Telomere length predicts replicative capacity of human fibroblasts. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[85]  J. Griffith,et al.  Mammalian Telomeres End in a Large Duplex Loop , 1999, Cell.

[86]  J. Shay,et al.  Telomerase activity in human germline and embryonic tissues and cells. , 1996, Developmental genetics.

[87]  R. DePinho,et al.  Essential role of mouse telomerase in highly proliferative organs , 1998, Nature.

[88]  M. Maitland,et al.  A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors , 2008 .

[89]  E. Blackburn,et al.  Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines , 1996, Molecular and cellular biology.

[90]  E. Blackburn,et al.  A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis , 1989, Nature.

[91]  R. Wurm,et al.  Telomere shortening triggers a p53-dependent cell cycle arrest via accumulation of G-rich single stranded DNA fragments , 1999, Oncogene.

[92]  E. Blackburn,et al.  ATM mediates cytotoxicity of a mutant telomerase RNA in human cancer cells. , 2008, Cancer research.

[93]  C. Streutker,et al.  Telomerase Activity as a Prognostic Factor in Neuroblastomas , 2001, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[94]  J. Shay,et al.  A survey of telomerase activity in human cancer. , 1997, European journal of cancer.

[95]  C. Osborne,et al.  Telomerase activity and survival of patients with node-positive breast cancer. , 1997, Journal of the National Cancer Institute.

[96]  S. Rosenberg,et al.  Immunization of Patients with the hTERT:540-548 Peptide Induces Peptide-Reactive T Lymphocytes That Do Not Recognize Tumors Endogenously Expressing Telomerase , 2004, Clinical Cancer Research.

[97]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[98]  K. Fox,et al.  Phase I study of anti-CD25 mab daclizumab to deplete regulatory T cells prior to telomerase/survivin peptide vaccination in patients (pts) with metastatic breast cancer (MBC). , 2010 .

[99]  Raina A Tamakawa,et al.  Telomerase inhibition potentiates the effects of genotoxic agents in breast and colorectal cancer cells in a cell cycle-specific manner. , 2010, Cancer research.

[100]  K. Shin‐ya,et al.  The G-quadruplex ligand telomestatin inhibits POT1 binding to telomeric sequences in vitro and induces GFP-POT1 dissociation from telomeres in human cells. , 2006, Cancer research.

[101]  G. Nelson,et al.  ssDNA fragments induce cell senescence by telomere uncapping , 2008, Experimental Gerontology.

[102]  Ming-ming Zhang,et al.  Clinical significance of telomerase activity in peritoneal lavage fluid from patients with gastric cancer and its relationship with cellular proliferation. , 2007, World journal of gastroenterology.

[103]  A. Smogorzewska,et al.  Regulation of telomerase by telomeric proteins. , 2004, Annual review of biochemistry.

[104]  G. Mills,et al.  Telomere 3′ overhang‐specific DNA oligonucleotides induce autophagy in malignant glioma cells , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[105]  J. Nemunaitis,et al.  A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  J. Feigon,et al.  Quadruplex structure of Oxytricha telomeric DNA oligonucleotides , 1992, Nature.

[107]  J. Shay,et al.  Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors , 2002, Oncogene.

[108]  N. Bache,et al.  Protein Composition of Catalytically Active Human Telomerase from Immortal Cells , 2007, Science.

[109]  Hamid Morjani,et al.  Telomestatin-induced Telomere Uncapping Is Modulated by POT1 through G-overhang Extension in HT1080 Human Tumor Cells* , 2006, Journal of Biological Chemistry.

[110]  J. D. Watson Origin of Concatemeric T7DNA , 1972 .

[111]  W. Hahn,et al.  Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes , 2004, Clinical Cancer Research.

[112]  B. Gilchrest,et al.  Induction of apoptosis by telomere 3' overhang-specific DNA. , 2002, Experimental cell research.

[113]  S. Scott,et al.  Cancer stem cells - from initiation to elimination, how far have we reached? (Review). , 2009, International journal of oncology.

[114]  K. Collins Physiological assembly and activity of human telomerase complexes , 2008, Mechanisms of Ageing and Development.

[115]  E. Raymond,et al.  Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[116]  E. Blackburn,et al.  Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. , 2006, Cancer research.

[117]  A. Goldkorn,et al.  Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference , 2011, The Prostate.

[118]  W. Hahn,et al.  The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. , 1999, Immunity.

[119]  J. Shay,et al.  In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. , 2005, Cancer research.

[120]  K. Shin‐ya,et al.  G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3′ telomeric overhang in cancer cells , 2006, Oncogene.

[121]  M. Kudo,et al.  Development of a Novel Assay to Quantify Serum Human Telomerase Reverse Transcriptase Messenger RNA and Its Significance as a Tumor Marker for Hepatocellular Carcinoma , 2007, Oncology.

[122]  G. Sledge,et al.  Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC). , 2010 .

[123]  E. Blackburn,et al.  Telomere states and cell fates , 2000, Nature.

[124]  H. Körner,et al.  Metachronous cancer development in patients with sporadic colorectal adenomas—multivariate risk model with independent and combined value of hTERT and survivin , 2008, International Journal of Colorectal Disease.

[125]  Timothy D. Veenstra,et al.  A Human Telomerase Holoenzyme Protein Required for Cajal Body Localization and Telomere Synthesis , 2009, Science.

[126]  N. Senzer,et al.  A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[127]  Keiko Hiyama,et al.  Correlating telomerase activity levels with human neuroblastoma outcomes , 1995, Nature Medicine.

[128]  M. Eller,et al.  Telomere‐based DNA damage responses: a new approach to melanoma , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[129]  R. Reddel,et al.  Alternative lengthening of telomeres: models, mechanisms and implications , 2010, Nature Reviews Genetics.

[130]  Jialing Yuan,et al.  Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. , 2007, Cancer research.

[131]  Laurence H. Hurley,et al.  Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents , 2005, Nucleic acids research.

[132]  K. Kapila,et al.  A comparative study of telomerase activity in sputum, bronchial washing and biopsy specimens of lung cancer. , 2001, Lung cancer.

[133]  F. Millard,et al.  Phase I study of transgenic B lymphocyte immunization (TLI) against telomerase in androgen-independent prostate cancer (PC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  M. Cerone,et al.  Telomere maintenance by telomerase and by recombination can coexist in human cells. , 2001, Human molecular genetics.

[135]  L. Hu,et al.  Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant , 2010, British Journal of Cancer.

[136]  I. Ganly,et al.  Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase , 2003, Oncogene.

[137]  K. Hioki,et al.  Change in telomerase activity during human colorectal carcinogenesis. , 1999, Anticancer research.

[138]  A. Uchida,et al.  Telomerase activity and human telomerase reverse transcriptase mRNA expression are correlated with clinical aggressiveness in soft tissue tumors , 2002, Cancer.

[139]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[140]  Carlo Leonetti,et al.  Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. , 2007, The Journal of clinical investigation.

[141]  Robert A. Weinberg,et al.  Telomerase contributes to tumorigenesis by a telomere length-independent mechanism , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[142]  S. Aamdal,et al.  A phase I/II study of telomerase peptide vaccination in combination with chemotherapy in patients with stage IV malignant melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  T. Płusa,et al.  Telomerase activity in transthoracic fine-needle biopsy aspirates from non-small cell lung cancer as prognostic factor of patients' survival. , 2008, Lung cancer.

[144]  Ian A. White,et al.  CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. , 2008, The Journal of clinical investigation.

[145]  A. Protopopov,et al.  Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo , 2008, Leukemia.

[146]  B. Murphy,et al.  Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity , 2004, Cancer Gene Therapy.

[147]  N. Maitland,et al.  Prostate cancer stem cells: a new target for therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[148]  T. Płusa,et al.  Telomerase activity in transthoracic fine needle biopsy aspirates as a marker of peripheral lung cancer , 2007, Thorax.

[149]  S. Morrison,et al.  Efficient tumor formation by single human melanoma cells , 2008, Nature.

[150]  J. Shay,et al.  Telomerase activity as a novel marker of lung cancer and immune-associated lung diseases. , 1998, International journal of molecular medicine.

[151]  E. Blackburn,et al.  In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs , 1990, Nature.

[152]  I. Weissman,et al.  Cancer stem cell-directed therapies: recent data from the laboratory and clinic. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[153]  R. Crevoisier,et al.  High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[154]  R. Verdun,et al.  Replication and protection of telomeres , 2007, Nature.

[155]  Amy Lin,et al.  Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. , 2009, Cancer research.